TL;DR
Researchers have identified oxidized glutathione (GSSG) as a key metabolic indicator of carbapenem resistance in E. coli strains carrying the bla<sub>NDM-1</sub> gene. Supplementing with GSSG not only restores carbapenem susceptibility in vitro and in vivo but also enhances the antibiotic's effectiveness by disrupting the bacteria's redox balance and suppressing the resistance enzyme's production. This work proposes a novel metabolomics-driven strategy to combat antibiotic resistance.
What Problem Does This Paper Address?
The rise of multidrug-resistant bacteria, particularly Enterobacteriaceae harboring the bla<sub>NDM-1</sub> gene, poses a critical global health threat. NDM-1 is a potent enzyme that degrades nearly all β-lactam antibiotics, including carbapenems, rendering them ineffective. Despite extensive research, developing clinically viable NDM-1 inhibitors has been challenging. This paper addresses the need for alternative strategies to overcome NDM-1-mediated carbapenem resistance, exploring the metabolic underpinnings of this resistance and seeking ways to re-sensitize bacteria to existing antibiotics.
Methods
The study employed a multi-pronged approach:
- Non-targeted Metabolomics: This was the core technique used to identify metabolic differences between E. coli strains with and without the bla<sub>NDM-1</sub> gene. Liquid chromatography-high resolution mass spectrometry was used to profile intracellular metabolites.
- Checkerboard Microdilution Assays: Standard method to determine Minimum Inhibitory Concentrations (MICs) and assess synergistic effects between GSSG and carbapenems (meropenem and ertapenem). The Fractional Inhibitory Concentration Index (FICI) was calculated to quantify synergy.
- Time-Killing Curve Assays: Used to evaluate the bactericidal activity of GSSG, carbapenems, and their combination over time.
- Reactive Oxygen Species (ROS) Measurement: Assessed intracellular ROS levels using a fluorescence assay kit to understand the role of oxidative stress in antibiotic efficacy.
- ROS Inhibition Assays: Utilized antioxidants (ascorbic acid, thiourea, N-acetylcysteine) to determine if ROS production is essential for the synergistic effect.
- Gene Expression Analysis (qRT-PCR): Quantified the transcription levels of the bla<sub>NDM-1</sub> gene under different treatment conditions.
- Protein Expression Analysis (Western Blot): Confirmed the protein levels of the NDM-1 enzyme.
- Intracellular Antibiotic Concentration Measurement: Employed UHPLC-tandem quadrupole mass spectrometry to quantify the intracellular levels of meropenem in bacteria treated with and without GSSG.
- In Vivo Infection Models: Mouse models of intraperitoneal infection were used to evaluate the therapeutic efficacy of GSSG in combination with carbapenems, assessing bacterial loads in tissues and overall survival rates.
Datasets
The study utilized E. coli strains for experiments:
- E. coli DH5α (pHSG398) - susceptible strain
- E. coli DH5α (pHSG398/bla<sub>NDM-1</sub>) - resistant strain
- Wild-type E. coli 20SC1DM33 - resistant strain
- Various bla<sub>NDM-1</sub> variants (blaNDM-4, blaNDM-5, blaNDM-7, blaNDM-9) in different E. coli strains.
Raw metabolomic data were deposited at the China National Genomics Data Center of Open Archive for Miscellaneous Data under accession number OMIX005757.
Key Insights and Ideas
- Metabolic Reprogramming Underlies Resistance: The bla<sub>NDM-1</sub> gene doesn't just confer resistance by enzyme activity; it also induces a metabolic shift towards antioxidant stress, which counteracts the bactericidal effects of antibiotics that rely on oxidative damage.
- GSSG as a Metabolic Biomarker: Oxidized glutathione (GSSG) was found to be significantly downregulated in NDM-1-positive E. coli, suggesting it's a key indicator of this altered metabolic state.
- GSSG Restores Antibiotic Susceptibility: Supplementing with GSSG effectively reverses carbapenem resistance, making the bacteria susceptible to antibiotics they were previously resistant to.
- Dual Mechanism of GSSG Action: GSSG works through two primary mechanisms:
- Promoting ROS Production: It helps restore the necessary oxidative stress that carbapenem antibiotics exploit to kill bacteria.
- Inhibiting NDM-1 Expression: It directly reduces the production of the resistance enzyme, allowing more antibiotic to accumulate inside the bacterial cell.
- Metabolomics-Driven Drug Discovery: This study highlights the power of metabolomics in identifying novel therapeutic strategies by targeting bacterial metabolic vulnerabilities.
Key Results
- Synergistic Antibacterial Effect: GSSG demonstrated a significant synergistic effect with meropenem and ertapenem against bla<sub>NDM-1</sub>-carrying E. coli. FICI values were consistently ≤ 0.5, indicating synergy.
- MIC Reduction: The combination of GSSG and carbapenems reduced the MIC of meropenem and ertapenem by 4- to 16-fold, depending on the specific bla<sub>NDM-1</sub> variant.
- In Vitro Killing: Time-kill assays showed that the combination of GSSG and carbapenems reduced bacterial survival to <5% within 2 hours and <1% within 6 hours, compared to monotherapy which had minimal effect.
- In Vivo Efficacy: In a mouse model, the GSSG + meropenem combination significantly reduced bacterial loads in the liver and spleen by several orders of magnitude compared to monotherapy.
- Survival Improvement: The combination therapy increased the survival rate of infected mice to 73% after 5 days, compared to near 0% survival in untreated or monotherapy groups.
- ROS Modulation: GSSG alone increased intracellular ROS, and the combination of GSSG and meropenem led to a significant, more than twofold increase in ROS levels in resistant strains.
- Antibiotic Accumulation: Intracellular meropenem concentrations were significantly increased (29.7-fold in one strain) when GSSG was co-administered, confirming reduced hydrolysis.
- Gene/Protein Downregulation: qRT-PCR and Western blot showed that GSSG, especially in combination with meropenem, significantly decreased the expression of bla<sub>NDM-1</sub> and the NDM-1 protein.
Limitations and Future Work
- Limited Scope of NDM-1 Variants: While several NDM-1 variants were tested, the study primarily focused on bla<sub>NDM-1</sub>. Further investigation into the efficacy of GSSG against a broader range of NDM variants and other metallo-β-lactamases would be valuable.
- Mechanism of GSSG-Induced ROS: While GSSG was shown to increase ROS, the precise biochemical pathway by which it does so in this context could be further elucidated.
- Clinical Translation: The study demonstrates promising results in vitro and in vivo, but the transition to clinical application would require extensive pharmacokinetic, pharmacodynamic, and safety studies in humans.
- Potential for Resistance to Combination Therapy: As with any antibiotic treatment, the potential for bacteria to develop resistance to the GSSG-carbapenem combination over time warrants investigation.
- Future Directions: The authors propose using metabolomics to identify other metabolic adjuvants that can potentiate existing antibiotic lethality, offering a new avenue for combating antibiotic resistance. They also suggest exploring the broader applicability of this strategy to other antibiotic-resistant pathogens.
Summary updated